Inflammation Markers Do Not Mediate Effects of Aspirin, Folic Acid On Colorectal Adenomas
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Inflammation Markers Do Not Mediate Effects of Aspirin, Folic Acid On Colorectal Adenomas

OXFORD, United Kingdom -- October 13, 2009 -- Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute.

Aspirin has been shown to prevent the recurrence of colorectal polyps, but it’s not clear how it works. One hypothesis is that it may affect the levels of substances, such as C-reactive protein and others that are markers of inflammation.

To study this, Gloria Y.F. Ho, PhD, Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, and colleagues examined changes in plasma levels of 5 inflammation markers -- C-reactive protein, interleukin 6, tumour necrosis factor (TNF), soluble TNF receptor type 2, and IL-1 receptor antagonist -- at baseline and at year 3 of 884 subjects.

The trial had 3 aspirin groups (including an aspirin placebo group) and 2 folic acid groups (including a folate placebo group).

Changes in levels of all 5 inflammation markers were not associated with adenoma recurrence. For those who did not receive folic acid, C-reactive protein levels in those in the 325 mg/d aspirin group changed very little, whereas it was statistically significantly increased in the placebo group. For subjects who received folic acid, the reverse association was observed.

“Our data suggest that low dose aspirin has modest effects on stabilising [C-reactive protein], which may be abrogated by a high level of folate,” the authors wrote. “However, such beneficial effects do not appear to confer protection against colorectal neoplasia. Inflammation markers do not mediate the previously observed effects of aspirin and folic acid on colorectal adenomas.”

SOURCE: Journal of the National Cancer Institute

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities